Identification of stabilized dynorphin derivatives for suppressing tolerance in morphine-dependent rats

Pharmaceutical Research

Volumn 21, Issue 8, 2004, Pages 1450-1456

  Al Fayoumi, Suliman I ^a   Brugos, Boglarka ^a   Arya, Vikram ^a   Mulder, Esther ^a   Eppler, Barbel ^b   Mauderli, Andre P ^a   Hochhaus, Günther ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b NANO ADM Advanced Development and Manufacturing Center   (United States)

Author keywords

dynorphin A(1 10) metabolism; dynorphin A(1 13); enzyme inhibition study; suppression of morphine tolerance

Indexed keywords

AMIDE; CAPTOPRIL; DEXTRO TYROSYLDYNORPHIN A AMIDE; DRUG METABOLITE; DYNORPHIN DERIVATIVE; ENZYME INHIBITOR; MORPHINE; N METHIONYLTYROSYLDYNORPHIN A AMIDE; UNCLASSIFIED DRUG;

ADULT; AMIDATION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG TOLERANCE; EXPERIMENTAL RAT; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; MALE; MASS SPECTROMETRY; MORPHINE ADDICTION; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN STABILITY; RAT; SEPARATION TECHNIQUE; STATISTICAL SIGNIFICANCE; TAIL FLICK TEST;

AMINOPEPTIDASES; ANALGESICS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; CARBOXYPEPTIDASES; DRUG STABILITY; DRUG TOLERANCE; DYNORPHINS; ENZYME INHIBITORS; HALF-LIFE; LEUCINE; MALE; MORPHINE DEPENDENCE; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; SUCCINATES; SULFHYDRYL COMPOUNDS;

EID: 4344678862     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000036920.50291.5b     Document Type: Article

References (33)

1. M. F. Powell, H. Grey, F. Gaeta, A. Sette, and S. Colon. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J. Pharm. Sci. 81:731-735 (1992).
2. M. D. Aceto, W. L. Dewey, J. K. Chang, and N. M. Lee. Dynorphin-(1-13): effects in non-tolerant and morphine -dependent rhesus monkeys. Eur. J. Pharmacol. 83:139-142 (1982).
3. P. G. Green and N. M. Lee. Dynorphin A(1-13) attenuates withdrawal in morphine-dependent rats: Effect of route of administration. Eur. J. Pharmacol. 145:267-272 (1988).
4. A. E. Takemori, H. H. Loh, and N. M. Lee. Suppression by dynorphin A(1-13) of the expression of opiate withdrawal and tolerance in mice. Eur. J. Pharmacol. 221:223-226 (1992).
5. H. Wen and W. Ho. Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur. J. Pharmacol. 82:183-186 (1982).
6. L. P. Hooke and N. M. Lee. Dynorphin A modulates acute and chronic opioid effects. J. Pharmacol. Exp. Ther. 273:292-297 (1995).
7. F. C. Tulunay, M. F. Jen, J. K. Chang, H. H. Loh, and N. M. Lee. Possible regulatory role of dynorphin on morphine- and endorphin-dependent analgesia. J. Pharmacol. Exp. Ther. 219:296-298 (1981).
8. 1] Dynorphin A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay. J. Pharmacol. Exp. Ther. 273:802-807 (1995).
9. H. L. Wen, W. K. K. Ho, and P. Y. Wen. Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur. J. Pharmacol. 100:155-162 (1984).
10. T. Uneklabh, P. Sintavanarong, V. Wessagowit, and L. Lunkanapiochonchut. Clinical effect of dynorphin on heroin addicts. J. Med. Assoc. Thai. 78:509-516 (1995).
11. S. Specker, W. Wananukul, D. Hatsukami, K. Nolin, L. Hooke, M. J. Kreek, and P. R. Pentel. Effects of dynorphin A(1-13) on opiate withdrawal in humans. Psychopharmacology (Berl.) 137:326-332 (1998).
12. S. Muller and G. Hochhaus. Metabolism of dynorphin A(1-13) in human blood and plasma. Pharm. Res. 12:1165-1170 (1995).
13. P. L. Gambus, T. W. Schnider, C. F. Minto, E. J. Youngs, V. Billard, W. G. Brose, G. Hochhaus, and S. L. Shafer. Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers. Clin. Pharmacol. Ther. 64:27-38 (1998).
14. F. Haviv, T. D. Fitzpatrick, R. E. Swenson, C. J. Nichols, N. A. Mort, E. N. Bush, G. Diaz, G. Bammert, A. Nguyen, and N. S. Rhutasel. Effect of N-methyl substitution of the peptide bonds in luteinizing hormone-releasing hormone agonists. J. Med. Chem. 36:363-369 (1993).
15. D. E. Benovitzand and A. F. Spatola. Enkephalin pseudopeptides: resistance to in vitro proteolytic degradation afforded by amide bond replacements extends to remote sites. Peptides 6:257-261 (1985).
16. 2, in mice. Br. J. Pharmacol. 132:1948-1956 (2001).
17. J. P. Meyer, T. J. Gillespie, S. Hom, V. J. Hruby, and T. P. Davis. In vitro stability of some reduced peptide bond pseudopeptide analogues of dynorphin A. Peptides 16:1215-1219 (1995).
18. A. T. Hagler, D. J. Osguthorpe, P. Dauber-Osguthorpe, and J. C. Hempel. Dynamics and conformational energetics of a peptide hormone: vasopressin. Science 227:1309-1315 (1985).
19. T. S. Shippenberg, M. Funada, and C. G. Schutz. Dynorphin A(2-17) attenuates the unconditioned but not the conditioned effects of opiate withdrawal in the rat. Psychopharmacology (Berl.) 151:351-358 (2000).
20. R. C. Caudle and A. J. Mannes. Dynorphin: friend or foe? Pain 87:235-239 (2000).
21. S. Woo, J. Garzon, P. Sanchez-Blazquez, F. C. Tulunay, J. K. Chang, and H. H. Loh. Dynorphin(1-10)amide: a potent and selective analog of dynorphin(1-13). Life Sci. 31:1817-1820 (1982).
22. P. R. Pentel, W. Wananukul, L. P. Hooke, C. R. N. Jones, D. Hatsukami, W. R. Anderson, and N. M. Lee. Effects of high intravenous doses of dynorphin A(1-13) on tail flick latency and central nervous system histology in rats. Pharm. Biochem. Behav. 51:387-390 (1995).
23. F. E. Damourand and D. L. Smith. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:74-79 (1941).
24. A. B. Lohmann and F. L. Smith. Buprenorphine substitution ameliorates spontaneous withdrawal in fentanyl-dependent rat pups. Pediatr. Res. 49:50-55 (2001).
25. L. S. Harris and A. K. Pierson. Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther. 143:141-148 (1964).
26. R. A. Skidgel and E. G. Erdos. Novel activity of human angiotensin I converting enzyme: release of the NH2- and COOH-terminal tripeptides from the luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 82:1025-1029 (1985).
27. R. A. Skidgel, S. Engelbrecht, A. R. Johnson, and E. G. Erdos. Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase. Peptides 5:769-776 (1984).
28. R. A. Skidgel, D. K. Weerasinghe, and E. G. Erdos. Structure of human carboxypeptidase N (kininase I). Adv. Exp. Med. Biol. 247A:325-329 (1989).
29. H. S. Cheung, F. L. Wang, M. A. Ondetti, E. F. Sabo, and D. W. Cushman. Binding of peptide substrates and inhibitors of angiotensin-converting enzyme. Importance of the COOH-terminal dipeptide sequence. J. Biol. Chem. 255:401-407 (1980).
30. I. Lantzand and L. Terenius. High enkephalyl peptide degradation, due to angiotensin-converting enzyme-like activity in human CSF. FEBS Lett. 193:31-34 (1985).
31. A. M. Kawasaki, R. J. Knapp, A. Walton, W. S. Wire, T. Zalewska, H. I. Yamamura, F. Porreca, T. F. Burks, and V. J. Hruby. Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions, 1, 6, 7, 8 and 10. Int. J. Pept. Protein Res. 42:411-419 (1993).
32. A. E. Takemori, H. H. Loh, and N. M. Lee. Suppression by dynorphin A and [des-Tyr1]-dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J. Pharmacol. Exp. Ther. 266:121-124 (1993).
33. T. Nakazawa, Y. Furuya, T. Kaneko, K. Yamatsu, H. Yoshino, and S. Tachibana. Analgesia produced by E-2078, a systemically active dynorphin analog, in mice. J. Pharmacol. Exp. Ther. 252:1247-1254 (1990).